TIDMYGEN
RNS Number : 1467N
Yourgene Health PLC
18 January 2023
Yourgene Health plc
("Yourgene" or the "Company")
Director/PDMR Shareholding
Manchester, UK - 18 January 2023: Yourgene (AIM: YGEN), a
leading international molecular diagnostics group, announces that
it was notified on 16 January 2023 that Bill Chang, Chief
Entrepreneur of the Company, purchased 920,000 ordinary shares of
0.1p each in the Company ("Ordinary Shares") on 13 January 2023 at
a price of 0.37p per share.
Furthermore, the Company was notified on 17 January 2023 that
Bill Chang purchased a further 13,000,000 Ordinary Shares on 17
January 2023 at a price of 0.43p per share.
Following the purchases, Bill Chang is interested in
302,920,142(1) Ordinary Shares, representing approximately 9.53 per
cent. of the Company's issued share capital.
(1) 280,000,142 Ordinary Shares are held by Changsform
Innovations Pte Ltd, Bill Chang is a company director and
beneficial owner of Changsform Innovations Pte Ltd.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this
announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Singer Capital Markets (Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / Mob: 07584 391
303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises integrated genomic technologies
and services enabling genomic medicine in over 60 territories. The
group works in partnership with global leaders in DNA technology to
advance diagnostic science and support precision medicine.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and an extension into the precision medicine
space with DPYD genotyping.
Yourgene has a range of innovative DNA sample preparation
platforms, and launched Yourgene Genomic Services in 2020, which
has enabled Yourgene to offer a global laboratory service network
equipped to provide high quality genetic testing and bioinformatics
solutions and serve as a full life-cycle partner for clinical,
research and pharmaceutical organisations to support partners at
the preclinical, clinical, and post-market stages to develop,
manufacture, obtain regulatory approval and commercialise new
products and services.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Dr Bill Chang
--------------------------------------- ----------------------------------
Reason for the notification
2
---------------------------------------------------------------------------
a) Position/status Chief Entrepreneur
--------------------------------------- ----------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ----------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Yourgene Health plc
--------------------------------------- ----------------------------------
b) LEI 213800UUIT8BZE7QEH33
--------------------------------------- ----------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the Ordinary shares of 0.1p each
financial instrument,
type of instrument
Identification code ISIN: GB00BN31ZD89
b) Nature of the transaction Purchase of ordinary shares
--------------------------------------- ----------------------------------
c) Price(s) and volume(s)
-------------- ---------------
Price(s) Volume(s)
-------------- ---------------
0.37p 920,000
-------------- ---------------
d) Aggregated information
- Aggregated volume N/A
- Price N/A
e) Date of the transaction 13 January 2023
--------------------------------------- ----------------------------------
f) Place of the transaction London
--------------------------------------- ----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Dr Bill Chang
--------------------------------------- ----------------------------------
Reason for the notification
2
---------------------------------------------------------------------------
a) Position/status Chief Entrepreneur
--------------------------------------- ----------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------------------- ----------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Yourgene Health plc
--------------------------------------- ----------------------------------
b) LEI 213800UUIT8BZE7QEH33
--------------------------------------- ----------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the Ordinary shares of 0.1p each
financial instrument,
type of instrument
Identification code ISIN: GB00BN31ZD89
b) Nature of the transaction Purchase of ordinary shares
--------------------------------------- ----------------------------------
c) Price(s) and volume(s)
-------------- ---------------
Price(s) Volume(s)
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
0.43p 1,000,000
-------------- ---------------
d) Aggregated information
- Aggregated volume 13,000,000
- Price 0.43p
e) Date of the transaction 17 January 2023
--------------------------------------- ----------------------------------
f) Place of the transaction London
--------------------------------------- ----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHLVLFFXFLBBBQ
(END) Dow Jones Newswires
January 18, 2023 07:07 ET (12:07 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024
